Core Viewpoint - Treace Medical Concepts, Inc. is set to showcase new product innovations and present interim data from its clinical studies at the ACFAS Annual Scientific Conference, emphasizing advancements in surgical treatments for bunions and related midfoot deformities [1][2]. Product Innovations - The company will highlight next-generation Lapiplasty instrumentation and fixation technology platforms, including SpeedTMT, Lapiplasty Lightning System, Nanoplasty, Percuplasty, SpeedMTP, and IntelliGuide PSI, aimed at enhancing surgical outcomes and market penetration [2][4]. - SpeedTMT is a new Lapiplasty fixation option utilizing hybrid technology, expected to be fully commercialized in the second half of 2026 [4]. - The Lapiplasty Lightning System is designed for greater accuracy and control in 3D correction, with full commercialization anticipated in late 2026 [4]. - Nanoplasty and Percuplasty are minimally invasive systems designed for efficient access to 3D osteotomies, with unique features to enhance surgical precision and recovery [4]. Clinical Study Presentations - The ALIGN3D clinical study will present interim data showing early return to weight bearing at an average of 8.4 days and low recurrence rates of 8.4% at 48 months [5][6]. - The MTA3D clinical study will present interim analysis demonstrating significant improvements in radiographic measures and patient-reported outcomes through 24 months [12]. - A retrospective study on the SpeedMTP system will show early return to weight bearing at an average of 3.7 days, with full radiographic union achieved in all patients at 6 months [8]. Company Overview - Treace Medical Concepts aims to advance the standard of care for bunion and midfoot deformities, addressing a significant market with approximately 67 million affected Americans, of which 1.1 million are surgical candidates annually [14]. - The company has developed the Lapiplasty 3D Bunion Correction System, which corrects bunion deformities in all three planes and secures the unstable joint, facilitating patient recovery [14].

Core Viewpoint - Treace Medical Concepts, Inc. is set to release its financial results for Q4 and the full year of 2025 on February 27, 2026, with a conference call scheduled for 8:00 am ET to discuss these results [1]. Company Overview - Treace Medical Concepts is a medical technology company focused on improving surgical treatments for bunions and related midfoot deformities, which affect approximately 67 million Americans, with an estimated 1.1 million being surgical candidates annually [4]. - The company has developed the patented Lapiplasty 3D Bunion Correction System, which aims to correct bunion deformities in three dimensions and stabilize the affected joint, addressing the root cause of the condition [4]. - Treace also offers additional systems such as the Adductoplasty Midfoot Correction System and minimally invasive options like the Nanoplasty 3D and Percuplasty™ systems, along with the SpeedMTP System [4]. - The company is expanding its market presence by extending its SpeedPlate rapid compression implant platform and providing advanced digital solutions for pre-operative planning [4].